Reports FY22 revenue $215M, consensus $213.31M. Zai Lab reported a net loss of $443.3M, or a loss per share attributable to common stockholders of $ 46c, for 2022, compared to a net loss of $704.5M, or a loss per share attributable to common stockholders of 76c, for 2021. The decrease in the net loss was primarily attributable to payments related to new business development activities.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZLAB:
- Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in March Investor Conferences
- Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
- Zai Lab announces NMPA in China accepted NDA of SUL-DUR
- Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
